AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2832287 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study 29943054 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-guided TAP block with 20 ml of 0.25% bupivacaine
Number of subjects: 90
Study 29943054 — intervention group
Group type: COMPARATOR
Intervention: Standard port site infiltration with 3-5 ml of 0.25% bupivacaine
Number of subjects: 90
Study 27994001 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg folic acid/day for 90 days
Number of subjects: 46
Study 27994001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 27994001 — intervention group
Group type: COMPARATOR
Intervention: Pre-fortification sperm DNA methylation profiles
Number of subjects: 46
Study 25711262 — intervention group
Group type: EXPERIMENTAL
Intervention: air‐Q® (air‐Q)
Number of subjects: 22
Study 25711262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu® aura‐i (aura‐i)
Number of subjects: 22
Study 25711262 — intervention group
Group type: EXPERIMENTAL
Intervention: i‐gel® (i‐gel)
Number of subjects: 22
Study 23547511 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) applied locally (6 ml)
Number of subjects: 28
Study 23547511 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRF applied)
Number of subjects: 28
Study 21372003 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 73
Study 21372003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 19655334 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline infusion
Number of subjects: 982
Study 19655334 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 982
Study 19655334 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygeline infusion
Number of subjects: 982
Study 19655334 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 982
Study 17919563 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal protection
Number of subjects: 594
Study 17919563 — intervention group
Group type: COMPARATOR
Intervention: Distal protection
Number of subjects: 594
Study 15353455 — intervention group
Group type: EXPERIMENTAL
Intervention: Open venous reservoir (15 patients)
Number of subjects: 30
Study 15353455 — intervention group
Group type: COMPARATOR
Intervention: Closed venous reservoir (15 patients)
Number of subjects: 30
Study 11872276 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) 54 Gy in 6 weeks
Number of subjects: 311
Study 11872276 — intervention group
Group type: COMPARATOR
Intervention: No treatment after surgery until tumor progression (Control)
Number of subjects: 311
Study 9672056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (nortriptyline hydrochloride)
Number of subjects: 0
Study 9672056 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 0
Study 9672056 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary physician
Number of subjects: 0
Study 9672056 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy relative to usual care
Number of subjects: 0
Study 9672056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 7601178 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAID felbinac
Number of subjects: 0
Study 7601178 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs (ibuprofen, fenbufen)
Number of subjects: 0
Study 2584638 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (Group 2)
Number of subjects: 20
Study 2584638 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (Group 1)
Number of subjects: 20
Study 2584638 — intervention group
Group type: COMPARATOR
Intervention: Both types of anesthesia
Number of subjects: 20
Study 31467314 — intervention group
Group type: EXPERIMENTAL
Intervention: HHR‐LNF (HHR with laparoscopic Nissen fundoplication)
Number of subjects: 122
Study 31467314 — intervention group
Group type: COMPARATOR
Intervention: HHR (Hiatal hernia repair)
Number of subjects: 122
Study 31467314 — intervention group
Group type: EXPERIMENTAL
Intervention: HHR‐LNF
Number of subjects: 122
Study 28737627 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 (10-valent pneumococcal conjugate vaccine)
Number of subjects: 47000
Study 28737627 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 47000
Study 28737627 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV10
Number of subjects: 47000
Study 25097089 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block + distal median, radial, and ulnar nerve blocks
Number of subjects: 62
Study 25097089 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block only
Number of subjects: 62
Study 23283428 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 3 mg/kg
Number of subjects: 10
Study 23283428 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 10
Study 20636448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient physiotherapy in warm climate (Spain)
Number of subjects: 60
Study 20636448 — intervention group
Group type: COMPARATOR
Intervention: Inpatient physiotherapy in cold climate (Norway)
Number of subjects: 60
Study 20077983 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified counseling (Therapeutic Conversation)
Number of subjects: 30
Study 20077983 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 30
Study 16962345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg ex‐actuator (equivalent to 400 microg ex‐valve)
Number of subjects: 399
Study 16962345 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg
Number of subjects: 399
Study 16962345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 399
Study 16962345 — intervention group
Group type: COMPARATOR
Intervention: Budesonide
Number of subjects: 399
Study 14987187 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt position during physiotherapy treatment
Number of subjects: 20
Study 14987187 — intervention group
Group type: COMPARATOR
Intervention: Flat side-lying position during physiotherapy treatment
Number of subjects: 20
Study 14987187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment (both positions)
Number of subjects: 20
Study 11150262 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-filled eyes with 10% to 15% gas volume
Number of subjects: 9
Study 11150262 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-filled eyes with 20% gas volume
Number of subjects: 9
Study 11150262 — intervention group
Group type: COMPARATOR
Intervention: Contralateral control eyes
Number of subjects: 9
Study 9040032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) trabeculae
Number of subjects: 0
Study 9040032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine receptor stimulation (ADO) trabeculae, 125 micromol/l for 5 min
Number of subjects: 0
Study 9040032 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of K(ATP) channel with glibenclamide (GLI) trabeculae, 10 micromol/l
Number of subjects: 0
Study 9040032 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine pretreatment combined with glibenclamide (ADO+GLI) trabeculae
Number of subjects: 0
Study 9040032 — intervention group
Group type: COMPARATOR
Intervention: Simulated ischemia-reperfusion (I/R) trabeculae
Number of subjects: 0
Study 8164027 — intervention group
Group type: EXPERIMENTAL
Intervention: GM2/BCG vaccine
Number of subjects: 122
Study 8164027 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 122
Study 2500069 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mg of MMC on the day of surgery and 10 mg of MMC the day after surgery, started on tegafur at a dose of 600 mg/day 2 weeks after surgery
Number of subjects: 210
Study 2500069 — intervention group
Group type: COMPARATOR
Intervention: Group B: similarly treated with MMC and started on UFT at a dose of 600 mg/day 2 weeks after surgery
Number of subjects: 210
Study 1101081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (VCR) and Prednisone (Pred)
Number of subjects: 73
Study 1101081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (VCR), Prednisone (Pred), and Daunorubicin (DNR)
Number of subjects: 73
Study 1101081 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis with methotrexate, intrathecally, three times
Number of subjects: 73
Study 1101081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine and Prednisone reinduction therapy
Number of subjects: 73
Study 1101081 — intervention group
Group type: COMPARATOR
Intervention: Group A (VCR and Pred)
Number of subjects: 73
Study 1101081 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (VCR, Pred, and DNR)
Number of subjects: 73
Study 31883905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral approach in a dysmenorrhea support program (6 sessions)
Number of subjects: 60
Study 31883905 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 30757992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Attachment-Based Intervention (GABI)
Number of subjects: 78
Study 30757992 — intervention group
Group type: COMPARATOR
Intervention: Systematic Training for Effective Parenting (STEP)
Number of subjects: 78
Study 28531872 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-conditioning (animal paired with a happy face)
Number of subjects: 73
Study 28531872 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinction (animal without scared face)
Number of subjects: 73
Study 28531872 — intervention group
Group type: COMPARATOR
Intervention: Control (no fear reduction procedure)
Number of subjects: 73
Study 25303169 — intervention group
Group type: EXPERIMENTAL
Intervention: Step aerobic dance combined with upper‐body resistance training (SAR; N=15)
Number of subjects: 41
Study 25303169 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional aerobic dance (AD; N=11)
Number of subjects: 41
Study 25303169 — intervention group
Group type: COMPARATOR
Intervention: Sedentary time control (CON; N=15)
Number of subjects: 41
Study 22821424 — intervention group
Group type: EXPERIMENTAL
Intervention: Green-lipped mussel extract (3,000 mg/day)
Number of subjects: 38
Study 22821424 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate (3,000 mg/day)
Number of subjects: 38
Study 16521117 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol 30 mg/day
Number of subjects: 0
Study 16521117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 14525804 — intervention group
Group type: EXPERIMENTAL
Intervention: DeVilbiss AutoAdjust LT
Number of subjects: 29
Study 14525804 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoSet T
Number of subjects: 29
Study 14525804 — intervention group
Group type: COMPARATOR
Intervention: Fixed-pressure CPAP
Number of subjects: 29
Study 10524414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy combined with external irradiation (total of 60 Gy external + 10 Gy intraluminal brachytherapy)
Number of subjects: 94
Study 10524414 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (60 Gy)
Number of subjects: 94
Study 10524414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy combined with external irradiation (for tumors 5 cm or less)
Number of subjects: 94
Study 10524414 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (for tumors 5 cm or less)
Number of subjects: 94
Study 10524414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy combined with external irradiation (for Stage T1 and T2 disease)
Number of subjects: 94
Study 10524414 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (for Stage T1 and T2 disease)
Number of subjects: 94
Study 10524414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy combined with external irradiation (for Stage T3-4 disease)
Number of subjects: 94
Study 10524414 — intervention group
Group type: COMPARATOR
Intervention: External irradiation alone (for Stage T3-4 disease)
Number of subjects: 94
Study 7499713 — intervention group
Group type: EXPERIMENTAL
Intervention: Redeepening incisions
Number of subjects: 2
Study 7499713 — intervention group
Group type: COMPARATOR
Intervention: Single pass incisions (Control)
Number of subjects: 2
Study 1837550 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic teicoplanin (one single bolus intravenous injection before catheter insertion)
Number of subjects: 88
Study 1837550 — intervention group
Group type: COMPARATOR
Intervention: No teicoplanin (control group)
Number of subjects: 88
Study 6124424 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12
Study 6124424 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tofisopam
Number of subjects: 12
Study 6124424 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg tofisopam
Number of subjects: 12
Study 6124424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31753032 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR therapy (nine sessions, around 60 min each, delivered weekly)
Number of subjects: 46
Study 31753032 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (routine care)
Number of subjects: 46
Study 27876105 — intervention group
Group type: COMPARATOR
Intervention: Cognition-focused (CF) intervention
Number of subjects: 65
Study 27876105 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) intervention
Number of subjects: 65
Study 24255546 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy and patient education
Number of subjects: 109
Study 24255546 — intervention group
Group type: COMPARATOR
Intervention: Patient education only
Number of subjects: 109
Study 23415623 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-recall program (intervention group, 201 participants)
Number of subjects: 403
Study 23415623 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the existing cervical screening program (control group, 202 participants)
Number of subjects: 403
Study 21694601 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐day awareness program
Number of subjects: 344
Study 21694601 — intervention group
Group type: COMPARATOR
Intervention: 1‐day awareness program
Number of subjects: 344
Study 18448211 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, oral ADV‐4 and ADV‐7 vaccines administered in a single dose to 30 subjects.
Number of subjects: 30
Study 18448211 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to 28 subjects.
Number of subjects: 30
Study 17285717 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate ointment
Number of subjects: 120
Study 12806612 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal diclofenac (100 mg)
Number of subjects: 220
Study 12806612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 10741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRN) administered by a 1-h i.v. infusion at doses of 20, 24, or 29 mg/m2 daily for 5 consecutive days for 2 weeks.
Number of subjects: 0
Study 10741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRN) at doses of 20, 24, and 29 mg/m2.
Number of subjects: 0
Study 10741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRN) after dose 1.
Number of subjects: 0
Study 10741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (IRN) and its metabolites.
Number of subjects: 0
Study 10741701 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted schedule of administration of Irinotecan (IRN).
Number of subjects: 0
Study 8900703 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided learning (CAL) lessons in diabetes management
Number of subjects: 36
Study 8900703 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes classes conducted by diabetes educators
Number of subjects: 36
Study 1801155 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg of amocarzine once daily (12 patients)
Number of subjects: 71
Study 1801155 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of amocarzine twice daily (59 patients)
Number of subjects: 71
Study 6410759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 42
Study 6410759 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 42
Study 6410759 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 42
Study 6410759 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine or Pergolide
Number of subjects: 42
Study 30908139 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-run patient navigation intervention
Number of subjects: 49
Study 30908139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 30309839 — intervention group
Group type: COMPARATOR
Intervention: Lycopene capsule (15 mg)
Number of subjects: 133
Study 30309839 — intervention group
Group type: COMPARATOR
Intervention: Lycopene-enriched diet
Number of subjects: 133
Study 30309839 — intervention group
Group type: COMPARATOR
Intervention: Active capsule group (EGCG 600 mg)
Number of subjects: 133
Study 30309839 — intervention group
Group type: COMPARATOR
Intervention: Green tea drink (3 cups)
Number of subjects: 133
Study 28206898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish application
Number of subjects: 200
Study 28206898 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish application
Number of subjects: 200
Study 25297016 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine 90 mg/day (30 mg thrice daily)
Number of subjects: 278
Study 25297016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 25297016 — intervention group
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Number of subjects: 278
Study 22395120 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time data processing (RTP) system for cardiac output (CO) and mean arterial pressure (MAP) measurement
Number of subjects: 10
Study 22395120 — intervention group
Group type: COMPARATOR
Intervention: Post hoc data processing (PP)
Number of subjects: 10
Study 19320533 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine treatment for 6 months
Number of subjects: 54
Study 19320533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carotid IMT
Number of subjects: 54
Study 17462043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bran supplement with planned nursing interventions
Number of subjects: 0
Study 17462043 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 0
Study 16353060 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg) with Indapamide (1.25 mg) (Noliprel forte)
Number of subjects: 40
Study 16353060 — intervention group
Group type: COMPARATOR
Intervention: Captopril (50 mg) with Hydrochlorothiazide (25 mg) (Capozide)
Number of subjects: 40
Study 11955727 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon (Betaseron) 16 x 10(6) IU by i.v. bolus 3 days a week on Weeks 1, 3, and 5, given 30 minutes before radiation therapy.
Number of subjects: 123
Study 11955727 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone, 2 Gy per fraction, 5 days a week, for a total of 60 Gy over 6 weeks.
Number of subjects: 123
Study 11955727 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-interferon arm
Number of subjects: 123
Study 11955727 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 123
Study 9708687 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1g
Number of subjects: 293
Study 9708687 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1g plus codeine 60 mg
Number of subjects: 293
Study 9708687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 8520076 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (HD)
Number of subjects: 15
Study 8520076 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 15
Study 2281374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment group
Number of subjects: 45
Study 2281374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 307487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation
Number of subjects: 60
Study 307487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31331777 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 2116
Study 31331777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2116
Study 28368909 — intervention group
Group type: EXPERIMENTAL
Intervention: Asacol 2.4 g once daily (QD) for 48 weeks
Number of subjects: 604
Study 28368909 — intervention group
Group type: COMPARATOR
Intervention: Asacol 2.4 g three times daily (TID) for 48 weeks
Number of subjects: 604
Study 26409291 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab 0.05%
Number of subjects: 22
Study 26409291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 23571420 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 28
Study 23571420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22048576 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 100
Study 22048576 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol
Number of subjects: 100
Study 22048576 — intervention group
Group type: COMPARATOR
Intervention: Control (freshly extracted carious teeth)
Number of subjects: 100
Study 19101798 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic argon plasma coagulation (APC)
Number of subjects: 57
Study 19101798 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 57
Study 16461077 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg twice daily
Number of subjects: 658
Study 16461077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658